top of page

Referring patients to the Spravato Program:

For Providers:​​

  • If you are a provider referring a patient for our services, please fill out the form below.

For Self Referrals:​

  • If you are a patient seeking treatment, please fill out our self-referral form below.

Spravato
The new treatment for Depression

SPRAVATO® (esketamine) is an FDA-approved nasal spray for adults with treatment-resistant depression (TRD) who have not responded to at least two antidepressants. It is administered under medical supervision in a certified setting, with patients monitored for at least two hours. SRAVATO® works by targeting the NMDA receptor, influencing glutamate levels in the brain, and has shown rapid antidepressant effects in some patients.

Frequently Asked Questions

bottom of page